On Friday, I-Mab ADR (NASDAQ: IMAB) opened lower -2.73% from the last session, before settling in for the closing price of $1.10. Price fluctuations for IMAB have ranged from $0.84 to $2.08 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 1181.20%. Company’s average yearly earnings per share was noted 87.13% at the time writing. With a float of $76.81 million, this company’s outstanding shares have now reached $77.02 million.
Let’s determine the extent of company efficiency that accounts for 220 employees. In terms of profitability, gross margin is 100.0%, operating margin of -10017.88%, and the pretax margin is -12176.93%.
I-Mab ADR (IMAB) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of I-Mab ADR is 0.27%, while institutional ownership is 19.25%. The most recent insider transaction that took place on Jul 26 ’24, was worth 69,500.
I-Mab ADR (IMAB) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.15 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 87.13% per share during the next fiscal year.
I-Mab ADR (NASDAQ: IMAB) Trading Performance Indicators
Check out the current performance indicators for I-Mab ADR (IMAB). In the past quarter, the stock posted a quick ratio of 16.50. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 74.92.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.55, a number that is poised to hit -0.06 in the next quarter and is forecasted to reach -0.47 in one year’s time.
Technical Analysis of I-Mab ADR (IMAB)
Looking closely at I-Mab ADR (NASDAQ: IMAB), its last 5-days average volume was 0.28 million, which is a drop from its year-to-date volume of 0.66 million. As of the previous 9 days, the stock’s Stochastic %D was 37.67%. Additionally, its Average True Range was 0.10.
During the past 100 days, I-Mab ADR’s (IMAB) raw stochastic average was set at 28.66%, which indicates a significant decrease from 40.97% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 96.83% in the past 14 days, which was higher than the 81.39% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.0032, while its 200-day Moving Average is $1.3583. However, in the short run, I-Mab ADR’s stock first resistance to watch stands at $1.1400. Second resistance stands at $1.2100. The third major resistance level sits at $1.2800. If the price goes on to break the first support level at $1.0000, it is likely to go to the next support level at $0.9300. Should the price break the second support level, the third support level stands at $0.8600.
I-Mab ADR (NASDAQ: IMAB) Key Stats
There are currently 81,501K shares outstanding in the company with a market cap of 82.41 million. Presently, the company’s annual sales total 3,890 K according to its annual income of -206,440 K. Last quarter, the company’s sales amounted to 0 K and its income totaled 25,130 K.
